Esperion Therapeutics Inc. (NASDAQ:ESPR) shares traded up 7.4% during trading on Friday . The stock traded as high as $11.19 and last traded at $11.14, with a volume of 378,396 shares traded. The stock had previously closed at $10.37.

A number of research analysts have issued reports on ESPR shares. Barclays PLC lowered shares of Esperion Therapeutics from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $28.00 to $13.00 in a research note on Wednesday, June 29th. Lake Street Capital cut their price target on shares of Esperion Therapeutics from $80.00 to $27.00 and set a “buy” rating on the stock in a research note on Wednesday, June 29th. Credit Suisse Group AG lowered shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and cut their price target for the company from $23.00 to $10.00 in a research note on Wednesday, June 29th. JMP Securities restated a “buy” rating and set a $67.00 price target on shares of Esperion Therapeutics in a research note on Thursday, June 16th. Finally, Zacks Investment Research lowered shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, April 6th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $26.29.

The company’s 50 day moving average price is $14.79 and its 200 day moving average price is $16.14. The firm’s market capitalization is $250.78 million.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.09. On average, equities analysts anticipate that Esperion Therapeutics Inc. will post ($3.57) EPS for the current fiscal year.

In other Esperion Therapeutics news, Director Mark E. Mcgovern bought 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 6th. The stock was purchased at an average price of $10.00 per share, with a total value of $50,000.00. Following the transaction, the director now owns 600 shares in the company, valued at $6,000. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Timothy M. Mayleben purchased 7,000 shares of the firm’s stock in a transaction on Wednesday, May 4th. The stock was bought at an average price of $14.85 per share, with a total value of $103,950.00. Following the acquisition, the chief executive officer now owns 41,614 shares in the company, valued at $617,967.90. The disclosure for this purchase can be found here.

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.